Headquartered in Chicago, IL, Allscripts Healthcare (MDRX - Analyst Report) recently announced an expanded partnership with OptimizeRx, a Rochester, MI-based health technology software company.
Under the terms of the expanded partnership, OptimizeRx is set to acquire the entire LogRx inventory of Allscripts Healthcare. However, OptimizeRx will sell the Allscripts LogRx messaging solution later.
Notably, earlier in the quarter, Allscripts and OptimizeRx had signed an agreement as well, that automates voucher and copay savings support within the Touchworks electronic health record (EHR) platform.
We believe that strategic alliances between companies provide healthcare providers with a better care giving platform. Notably, the latest partnership is likely to provide the healthcare providers with an enhanced platform for financial messaging. In fact, per the previous expansion agreement, healthcare companies got an electronic platform to transfer prescription savings directly to the patient's pharmacy.
Meanwhile, Allscripts has been gaining prominence owing to a series of lucrative developments. Recently, the company announced Allscripts eRecruit services, a multi-faceted initiative to support physicians and ease out clinical trials by referring patients.
Of the other notable developments, Wise Health System recently selected Allscripts Sunrise and CareInMotion platforms to improve patient care and population health trends. In fact, the Sunrise platform was recently launched by the King’s College Hospital for its new health information system.
Stocks that Warrant a Look
A few notable stocks in broader medical sector include Halyard Health Inc. (HYH - Snapshot Report) , Straumann Holding AG (SAUHF - Snapshot Report) and ABIOMED Inc. (ABMD - Analyst Report) .
Halyard Health posted positive earnings surprises in the last four quarters, with the average being 25.8%. Meanwhile, a glimpse at the share price reveals an impressive one-year return of 14.2%.
Straumann has an impressive long-term expected earnings growth rate of 13%. The Zacks Consensus Estimate for earnings rose by a massive 83 cents in the current year, taking the figure to $12.09 per share.
ABIOMED posted positive earnings surprises in the last four quarters, the average being 34.9%. This stock has an impressive long-term expected earnings growth rate of 26.7%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>